GALLASCHUN RANDALL (US)
| AMENDED CLAIMS received by the International Bureau on 12 November 2014 (12.1 1 .2014) We claim: 1. A compound of Formula 1(a): Formula 1(a) or a pharmaceutically acceptable salt thereof, wherein: R1 is C\-Ce alkyl, C2-C6 alkenyl or C2-C6 alkynyl, each of which is optionally substituted with 1-4 R5; R is C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, halo, C1-C6 haloalkoxy, hydroxyl, C1-C6 alkoxy, C3-C7 cycloalkyloxy, C6-C10 aryl, C6-C10 aryloxy, C -Ci6 arylalkoxy, amino, C1-C6 alkylamino, C2-Q2 dialkylamino, -S-, -S-Ci-C6 alkyl, -S(O)-, - S(0)2", heterocycloalkyl, heteroaryl, heteroaryloxy, sulfonamidyl, amido, urea, sulfonylurea, acyl, nitro or cyano, wherein each of C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkoxy, C3-C7 cycloalkyloxy, C6-C10 aryl, C6- C10 aryloxy, C7-C16 arylalkoxy, amino, C1-C6 alkylamino, C2-C12 dialkylamino, -S-, -S-Ci-C6 alkyl, -S(O)-, -S(0)2-, heterocycloalkyl, heteroaryl, heteroaryloxy, sulfonamidyl, amido, urea, sulfonylurea and acyl, is optionally substituted with 1-3 R6; R is C2-C6 hydroxy alkyl or Ci-C6 heteroalkyl; R4 is Ci-C6 alkyl, Ci-C6 heteroalkyl, C2-C6 alkenyl or C2-C6 alkynyl, each of which is Q optionally substituted with 1-4 R ; R5, R6, and R8 are each independently Ci-C6 alkyl, Ci-C6 heteroalkyl, halo, Ci-C6 haloalkyl, Ci-C6 haloalkoxy, hydroxyl, Ci-C6 alkoxy, amino, Ci-C6 alkylamino, C2-C12 dialkylamino, cyano, nitro, amido, Ci-C6 alkylamido, C2-C12 dialkylamido, -S-, -S(0)2-, -C(0)0-, -C(O)-, -C(0)0-C C6 alkyl, C3-C7 cycloalkyl, C6-C10 aryl, heterocycloalkyl or heteroaryl, wherein each of Ci-C6 alkyl, Ci-C6 heteroalkyl, Ci-C6 haloalkyl, Ci-C6 haloalkoxy, Ci-C6 alkoxy, amino, Ci-C6 alkylamino, C2-C12 dialkylamino, amido, Ci-C6 alkylamido, C2-C12 dialkylamido, -S-, -S(0)2-, -C(0)0-, -C(O)-, -C(0)0-C1-C6 alkyl, C3-C7 cycloalkyl, C6-C10 aryl, heterocycloalkyl and heteroaryl is optionally substituted with 1-3 R9; and each R9 is independently C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, heterocycloalkyl, C6-C10 aryl, heteroaryl, C4-C10 cycloalkylalkyl, heterocycloalkyl- C1-C6 alkyl, C7-C16 arylalkyl, heteroaryl- C1-C6 alkyl, halo, hydroxyl, C1-C6 alkoxy, C6-C10 aryloxy, C7-C16 arylalkoxy, C2-C8 alkoxyalkoxyl, amino, C1-C6 alkylamino, C2-C12 dialkylamino, C1-C6 alkyl-amino-C1-C6 alkyl, C1-C6 alkyl-amino- C2-C12 dialkyl, -S-, -S-C1-C6 alkyl, -S(0)2-C1-C6 alkyl, sulfonamidyl, amido, urea, sulfonylurea, acyl, -C(0)-C6-Cio aryl, - NHC(O)-C6-C10 aryl, -C(O)NH-C6-C10 aryl, -C(0)OH, -C(0)0-C1-C6 alkyl, -C(0)-C1-C6 alkyl acyl, nitro or cyano. 2. The compound of claim 1 , wherein R1 is C1-C6 alkyl, optionally substituted with 1-4 R5. 3. The compound of claim 1 , wherein R is C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkoxy, C1-C6 alkoxy, C3-C7 cycloalkyloxy, C6-C10 aryl, C6-C10 aryloxy, C7-C16 arylalkoxy, amino, C1-C6 alkylamino, -S-, -S-C1-C6 alkyl, -S(O)-, -S(0)2-, heteroaryloxy or sulfonamidyl, optionally substituted with 1-3 R6. 4 8 4. The compound of claim 1 , wherein R is C1-C6 alkyl, optionally substituted with 1-4 R . 5. The compound of claim 1 , wherein R5 is C1-C6 haloalkyl, C1-C6 alkoxy, C6-C10 aryl, heterocycloalkyl, heteroaryl or C3-C7 cycloalkyl. 6. The compound of claim 1 , wherein R6 is C1-C6 alkyl, C1-C6 heteroalkyl, halo, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxyl, C1-C6 alkoxy, C2-C12 dialkylamino, cyano, -C(0)0-CrC6 alkyl, C3-C7 cycloalkyl, C6-C10 aryl, heterocycloalkyl or heteroaryl. 7. The compound of claim 1 , wherein R8 is C1-C6 haloalkyl, hydroxyl or heteroaryl. 8. The compound of claim 1 , wherein R9 is C1-C6 alkyl, C1-C6 heteroalkyl, halo, C1-C6 haloalkyl, C1-C6 haloalkoxy, amino, hydroxyl, C1-C6 alkoxy, C2-C12 dialkylamino, C1-C6 alkyl- amino-C1-C6 alkyl, C1-C6 alkyl-amino-C2-C12 dialkyl, heterocycloalkyl or cyano. 9. The compound of claim 1, wherein R is selected from the group consisting of: 10. The compound of claim 1, wherein R is selected from the group consisting of: | H_| O -N— S OH OH *^ OH ,NH, and 12. The compound of claim 1, wherein R is selected from the group consisting of: -CH, and 13. The compound of claim 1, wherein R is selected from the group consisting of: 14. The compound of claim 1, wherein R is selected from the group consisting of: *— CI *— F *-CH3 *-CF3 *— CN *— OH and 15. The compound of claim 1, wherein R is selected from the roup consisting of: 16. The compound of claim 1, wherein R is selected from the group consisting of: The compound of claim 1, wherein: *— CH3 *— CF3 *— CN *— CI *— F 9 is 18. A compound of Formula Formula III or a pharmaceutically acceptable salt thereof, wherein: R2 is Ci-C6 alkoxy or C6-C10 aryloxy substituted with 1-3 R6; R is C2-C6 hydroxy alkyl or Ci-C6 heteroalkyl; R4 is Ci-C6 alkyl; R is independently Ci-C6 alkyl, halo, Ci-C6 haloalkyl, Ci-C6 haloalkoxy or Ci-C6 alkoxy; each Ra is Ci-C6 alkyl, Ci-C6 haloalkyl or halo; n is 1 or 2; and m is 1 , 2, or 3. 19. The compound according to any of the preceding claims, wherein the compound is selected from the group consisting of: 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 20. A pharmaceutical composition comprising a compound according to any of the preceding claims, or a pharmaceutically acceptable salt thereof. 21. A method of treating a TRPC5 mediated disorder in a subject, the method comprising administering to the subject a compound or pharmaceutical composition according to any of the preceding claims to thereby treat the subject. 22. A method of treating a TRPC5 mediated disorder in a subject, the method comprising administering to the subject a compound or pharmaceutical composition according to any of the preceding claims to thereby treat the subject, wherein the TRPC5 mediated disorder is selected from the group consisting of: neuropsychiatric disorder, neurodegenerative disorder, nephropathy, and seizure disorder. 732 |
Next Patent: CLAD SHEET ALLOYS FOR BRAZING APPLICATIONS